Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Shareholder Meeting (May 2018)
18 slides from Imagion Biosystems's shareholder meeting presentation, May 2018
Slide 1: MagSense Technology AGM Update
® B I O S Y S T E M S MagSense™ Technology AGM Update A New Clinical Diagnostic May 2018 ASX:IBX Technology for Targeted Early www.imagionbiosystems.com Detection of Cancer
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Imagion Biosystems Limited (Imagion) for the benefit of accuracy, reasonableness or completeness of the information contained herein. Neither Imagion certain investors who are sophisticated or professional investors and wholesale clients (as those no
Slide 3: Cancer Diagnostics – A Large Market
Cancer Diagnostics – A Large Market $100B Global Cancer Diagnostics Market Cancer diagnostics is a $100 billion $30,000 market growing at a CAGR of >7%* $26,044 $25,000 with imaging techniques accounting $20,000 $20,136 for the largest portion. Our MagSense Millions $15,000 $15,541 technology is a n
Slide 4: The Opportunity in Cancer Diagnostics
The Opportunity in Cancer Diagnostics MARKET DRIVERS Cancer continues to be one of the leading causes of mortality globally despite technical advances in science and medicine made in the last 150 years. The consensus within the medical community and supported by the SEER Cancer Statistics is that mo
Slide 5: Significant Achievements in 2017/2018
Significant Achievements in 2017/2018 ü Successful initial public offering (ASX:IBX) raised A$12M, funding initial stages of translational development of MagSenseTM technology in preparation for first-in-human studies. ü Contract manufacturers Starfish Medical and ChemConnections engaged to assist w
Slide 6: Business Strategy to Create Value
Business Strategy to Create Value Detection Doctors and Office Therapy Primary Ubiquitous Nanoparticle Tumour like is both Staging Detection Ultrasound detection and delivery Breast Breast, of therapy Prostate, Cancer Lung, and $10’sB > $100B Shortest Path Ovarian to Clinical Proof $5B $500M 6
Slide 7: Next Steps and News Flow
Next Steps and News Flow Q3 2018 • Initiate pilot manufacture of GLP/cGMP compliant HER2 nanoparticle formulation for use in tox/safety studies. Q4 2018 • Completion of preclinical toxicology study to demonstrate safety before First-in-Human studies. Q4 2018 • Manufacture cGMP batch of HER2 nanopart
Slide 8: Business Fundamentals Summary
Business Fundamentals Summary Valuation Factors IBX’s Business MagSense is more sensitive than current Uniqueness of the device and extent of medical imaging and able to differentiate disruption of current medical practice benign from malignant tumors IBX owns and controls the IP for medical Strengt
Slide 9: Supplemental Material
Supplemental Material 9
Slide 10: Investment Highlights
Investment Highlights $100 Billion 8 Patents “Printer & Ink” model Annual global Core Product includes both the instrument and a spending on cancer technology diagnostic consumable. covered in diagnosis in imaging major markets and pathology. through to $2 Billion Platform 2029. Technology Addressab
Slide 11: Strong Board and Management
Strong Board and Management Robert Proulx Bronwyn Le Grice Michael Harsh John Hazle PhD Jovanka Naumoska Chairman & CEO Non Exec Director Non Exec Director Non Exec Director Corp Secretary • Operationally oriented • 15 years of experience • Former VP & CTO of GE • Board certified for both • Australi
Slide 12: How MagSense Technology Works
How MagSense Technology Works • A low dose of magnetic nanoparticles is given by intravenous injection and allowed to circulate and find the tumor. • The patent is positioned under the detector for measurement to see if any particles are detectable. • Only particles attached to the cancer cells will
Slide 13: How MagSense Technology Compares
How MagSense Technology Compares More Sensitive and Specific • MagSense technology is more sensitive than conventional imaging methods which will allow tumors to be detected and treated earlier. • Current imaging methods can not differentiate benign from malignant lesions but MagSense nanoparticles
Slide 14: Technology Development
Technology Development Key Scientific Collaborators • MD Anderson Cancer Center’s Department of Imaging Physics has a Magnetic Relaxometry Research Laboratory helping to validate the technology. • Experts in computational biology of magnetic fields at UCSD are assisting with technology development.
Slide 15: Breast Cancer Program
Breast Cancer Program Staging HER2 Breast Cancer • 20-25% of breast cancers are HER2 positive. • Following primary diagnosis patients are assessed for metastases by Sentinel Lymph Node Biopsy (SLNB). • 50-70% of patients are negative which results in unnecessary lymphadenectomy and lymphedema. • The
Slide 16: Ovarian Cancer Program
Ovarian Cancer Program “The Silent Killer” • If detected at an early stage (I or II), cytoreductive surgery and conventional chemotherapy can cure 70-90% of patients. • Only 20-25% of ovarian cancers are diagnosed in early stage I-II because ovarian cancer is typically asymptomatic, making it the si
Slide 17: Prostate Cancer Program
Prostate Cancer Program Minimizing Need for Prostate Biopsies • Prostate cancer is the second most frequent form of cancer found in men with approximately one in seven men being diagnosed with prostate cancer during their lifetime. • Early prostate cancer is largely asymptomatic and most prostate ca
Slide 18: Mitigating Risks
Mitigating Risks Risk Factors Operational Plan • Clinical studies and regulatory review üMagSense technology will be regulated will be required of MagSense technology as a medical device and not a drug. before commercialization. Clinical studies will not require large numbers of patients or lengthy